Nomenclature	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=560	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=561	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=562	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=563	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=564
HGNC, UniProt	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6294, http://www.uniprot.org/uniprot/P51787	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6296, http://www.uniprot.org/uniprot/O43526	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6297, http://www.uniprot.org/uniprot/O43525	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6298, http://www.uniprot.org/uniprot/P56696	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:6299, http://www.uniprot.org/uniprot/Q9NR82
Activators	–	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2601 (pEC50 5.6) [http://www.ncbi.nlm.nih.gov/pubmed/11466425?dopt=AbstractPlus]	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5483 (pEC50 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/30021858?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2601 (pEC50 6.2) [http://www.ncbi.nlm.nih.gov/pubmed/11466425?dopt=AbstractPlus]	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2601 (pEC50 5.2) [http://www.ncbi.nlm.nih.gov/pubmed/11466425?dopt=AbstractPlus]	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2601 (pEC50 5) [http://www.ncbi.nlm.nih.gov/pubmed/11890900?dopt=AbstractPlus]
Selective activators	–	–	–	–	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5483 (pEC50 8.7) [http://www.ncbi.nlm.nih.gov/pubmed/30021858?dopt=AbstractPlus]
Inhibitors	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2596 (pK d 6.1) [http://www.ncbi.nlm.nih.gov/pubmed/10825393?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2599 (pIC50 4.4) [http://www.ncbi.nlm.nih.gov/pubmed/12690036?dopt=AbstractPlus] – Mouse	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2596 (pIC50 6.2) [http://www.ncbi.nlm.nih.gov/pubmed/9836639?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2599 (pIC50 5.3) [http://www.ncbi.nlm.nih.gov/pubmed/9836639?dopt=AbstractPlus]	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2599 (pIC50 5.4) [http://www.ncbi.nlm.nih.gov/pubmed/9836639?dopt=AbstractPlus] – Rat	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2596 (pIC50 5.3) [http://www.ncbi.nlm.nih.gov/pubmed/11245603?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2599 (pIC50 4.9) [http://www.ncbi.nlm.nih.gov/pubmed/11245603?dopt=AbstractPlus]	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2599 (pK d 4.8) [http://www.ncbi.nlm.nih.gov/pubmed/10787416?dopt=AbstractPlus]
Sub/family‐selective inhibitors	–	–	–	–	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2596 (pIC50 4.2) [http://www.ncbi.nlm.nih.gov/pubmed/10816588?dopt=AbstractPlus]
Channel blockers	–	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343 (pIC50 3.5–3.9) [http://www.ncbi.nlm.nih.gov/pubmed/10711337?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/10953053?dopt=AbstractPlus]	–	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2343 (pIC50 1.3) [http://www.ncbi.nlm.nih.gov/pubmed/18786918?dopt=AbstractPlus]	–
Functional Characteristics	cardiac IK5	M current as a heteromer between KV7.2 and KV7.3	M current as heteromeric KV7.2/KV7.3 or KV7.3/KV7.5	–	M current as heteromeric KV7.3/KV7.5